Teachers Retirement System of The State of Kentucky Invests $4.09 Million in Insulet Co. (NASDAQ:PODD)

Teachers Retirement System of The State of Kentucky bought a new position in shares of Insulet Co. (NASDAQ:PODD – Get Rating) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 17,836 shares of the medical instruments supplier’s stock, valued at approximately $4,092,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Vanguard Group Inc. lifted its position in shares of Insulet by 1.0% during the third quarter. Vanguard Group Inc. now owns 6,392,621 shares of the medical instruments supplier’s stock worth $1,466,468,000 after purchasing an additional 64,742 shares during the last quarter. Clearbridge Investments LLC increased its stake in shares of Insulet by 38.8% during the first quarter. Clearbridge Investments LLC now owns 1,696,822 shares of the medical instruments supplier’s stock valued at $452,016,000 after buying an additional 474,545 shares during the period. Echo Street Capital Management LLC increased its stake in shares of Insulet by 0.6% during the second quarter. Echo Street Capital Management LLC now owns 807,643 shares of the medical instruments supplier’s stock valued at $176,018,000 after buying an additional 5,209 shares during the period. Fred Alger Management LLC increased its stake in shares of Insulet by 1.7% during the third quarter. Fred Alger Management LLC now owns 632,051 shares of the medical instruments supplier’s stock valued at $144,992,000 after buying an additional 10,308 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in shares of Insulet by 5.2% during the second quarter. Goldman Sachs Group Inc. now owns 616,690 shares of the medical instruments supplier’s stock valued at $134,402,000 after buying an additional 30,411 shares during the period.

Insider Buying and Selling

In related news, insider Charles Alpuche sold 23,401 shares of Insulet stock in a transaction dated Monday, March 13th. The stock was sold at an average price of $305.15, for a total transaction of $7,140,815.15. Following the completion of the sale, the insider now owns 45,584 shares of the company’s stock, valued at $13,909,957.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Charles Alpuche sold 23,401 shares of Insulet stock in a transaction dated Monday, March 13th. The stock was sold at an average price of $305.15, for a total transaction of $7,140,815.15. Following the completion of the sale, the insider now owns 45,584 shares of the company’s stock, valued at $13,909,957.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Shacey Petrovic sold 15,000 shares of Insulet stock in a transaction dated Wednesday, January 4th. The stock was sold at an average price of $281.88, for a total value of $4,228,200.00. Following the sale, the director now directly owns 14,789 shares of the company’s stock, valued at approximately $4,168,723.32. The disclosure for this sale can be found here. Insiders sold 46,401 shares of company stock valued at $13,647,895 over the last quarter. 0.90% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on PODD shares. Barclays raised their price target on Insulet from $245.00 to $292.00 in a research note on Friday, February 24th. Morgan Stanley raised their price target on Insulet from $320.00 to $325.00 and gave the company an “equal weight” rating in a research note on Friday, February 24th. Wolfe Research began coverage on Insulet in a research note on Thursday, January 26th. They issued a “peer perform” rating on the stock. StockNews.com began coverage on Insulet in a research note on Thursday. They issued a “hold” rating on the stock. Finally, Citigroup lifted their target price on Insulet from $270.00 to $330.00 in a research note on Monday, December 12th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $317.82.

Insulet Price Performance

Shares of NASDAQ PODD opened at $309.09 on Friday. The company has a debt-to-equity ratio of 2.88, a quick ratio of 2.65 and a current ratio of 3.60. The company has a market cap of $21.49 billion, a PE ratio of 5,151.50 and a beta of 0.75. The business has a 50-day simple moving average of $293.57 and a two-hundred day simple moving average of $278.64. Insulet Co. has a fifty-two week low of $181.00 and a fifty-two week high of $320.00.

Insulet (NASDAQ:PODD – Get Rating) last issued its quarterly earnings results on Thursday, February 23rd. The medical instruments supplier reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.31. The business had revenue of $369.70 million during the quarter, compared to the consensus estimate of $331.73 million. Insulet had a return on equity of 20.55% and a net margin of 0.35%. The company’s quarterly revenue was up 20.1% on a year-over-year basis. During the same quarter last year, the company earned $0.42 earnings per share. As a group, equities analysts expect that Insulet Co. will post 1.29 EPS for the current fiscal year.

Insulet Profile

(Get Rating)

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals.